Eton Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances at December 31, 2020	24,312,808	$24	$107,797	$(92,158)	$15,663
Stock-based compensation	—	—	3,381	—	3,381
Stock option exercises	144,233	1	338	—	339
Employee stock purchase plan	49,155	—	202	—	202
Common stock issued related to restricted stock units	25,000	—	—	—	—
Stock warrant exercises	94,808	—	—	—	—
Net loss	—	—	—	(1,955)	(1,955)
Balances at December 31, 2021	24,626,004	25	111,718	(94,113)	$17,630
Stock-based compensation	—	—	4,218	—	4,218
Stock option exercises	25,000	—	35	—	35
Employee stock purchase plan	69,884	—	171	—	171
Stock warrant exercises	632,231	—	45	—	45
Net loss	—	—	—	(9,021)	(9,021)
Balances at December 31, 2022	25,353,119	25	116,187	(103,134)	$13,078
Stock-based compensation	—	—	3,137	—	3,137
Employee stock purchase plan	86,782	—	229	—	229
Stock option exercises and vesting of restricted stock units	299,028	1	148	—	149
Shares withheld related to net share settlement of stock option exercises	(50,867)	—	(180)	—	(180)
Net loss	—	—	—	(936)	(936)
Balances at December 31, 2023	25,688,062	$26	$119,521	$(104,070)	$15,477

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.